Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 13/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | PDE8A | O60658 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | PDE9A | O76083 | 1/20 | 0.51 |
| ▸ | PDE6A | P16499 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828115 | 0.87 | SMPD3 (0.51) | SMPD3PDE10ACNR2 | |
| SCHEMBL1825986 | 0.87 | SMPD3 (0.51) | SMPD3PDE10APDE2APDE8APDE5A | |
| SCHEMBL1825191 | 0.86 | SMPD3 (0.66) | SMPD3PDE10APDE2APDE8APDE5A | |
| SCHEMBL1826556 | 0.85 | SMPD3 (0.62) | SMPD3PDE10APDE2APDE8APDE5A | |
| SCHEMBL2581458 | 0.85 | SMPD3 (0.48) | SMPD3PDE10APDE2APDE8APDE5A | |
| SCHEMBL1825696 | 0.84 | PDE10A (0.70) | PDE10APDE2APDE8APDE5APDE9A | |
| SCHEMBL1827861 | 0.82 | SMPD3 (0.63) | SMPD3PDE10APDE2APDE8APDE5A | |
| SCHEMBL1825860 | 0.82 | PDE10A (0.77) | SMPD3PDE10APDE2APDE8APDE5A | |
| SCHEMBL1825909 | 0.82 | PDE10A (0.49) | SMPD3PDE10A | |
| SCHEMBL1826823 | 0.82 | PDE10A (0.66) | PDE10APDE2APDE8APDE5APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | claimed |
| US-8716282-B2 | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | claimed |
| EP-2493889-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2012-09-05 | — | — | EP | claimed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | claimed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | claimed |
| WO-2011051342-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | claimed |
| EP-2863909-B1 | COMBINATIONS COMPRISING 4-METHYL-[1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AS PDE 2 INHIBITORS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-04 | — | — | EP | disclosed |
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-9669035-B2 | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-06 | — | — | US | disclosed |
| US-20150366873-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO-[4,3-A]]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OF METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-24 | — | — | US | disclosed |
| EP-2863909-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO [4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | Janssen Pharmaceutica N.V. (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-8716282-B2 | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| WO-2014001314-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4] TRIAZOLO [4,3-A] QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-03 | — | — | WO | disclosed |
| EP-2493889-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| WO-2011051342-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | SMPD3 64/4885PDE10A 2/4885PDE2A 4/4885 |
| US-20150366873-A1 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO-[4,3-A]]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OF METABOLIC DISORDERS | PDE12, PDE5A, PDE2A | SMPD3 210/4885PDE10A 4/4885PDE2A 3/4885 |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | SMPD3 64/4885PDE10A 2/4885PDE2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.